Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term cancer-patients. Found 15 abstracts

Chakravarty A, Shinde V, Tabernero J, Cervantes A, Cohen RB, Dees EC, Burris H, Infante JR, Macarulla T, Elez E, Andreu J, Rodriguez-Braun E, Rosello S, von Mehren M, Meropol NJ, Langer CJ, Oneil B, Bowman D, Zhang M, Danaee H, Faron-Yowe L, Gray G, Liu H, Pappas J, Silverman L, Simpson C, Stringer B, Tirrell S, Veiby OP, Venkatakrishnan K, Galvin K, Manfredi M, Ecsedy JA. Phase I Assessment of New Mechanism-Based Pharmacodynamic Biomarkers for MLN8054, a Small-Molecule Inhibitor of Aurora A Kinase. Cancer Research. 2011 Feb;71(3):675-85.   PMCID: not NIH funded
Kanetsky PA, Mitra N, Vardhanabhuti S, Vaughn DJ, Li MY, Ciosek SL, Letrero R, D'Andrea K, Vaddi M, Doody DR, Weaver J, Chen C, Starr JR, Hakonarson H, Rader DJ, Godwin AK, Reilly MP, Schwartz SM, Nathanson KL. A second independent locus within DMRT1 is associated with testicular germ cell tumor susceptibility. Human molecular genetics. 2011 Aug;20(15):3109-17.   PMCID: PMC3131044
Slingluff CL, Petroni GR, Chianese-Bullock KA, Smolkin ME, Ross MI, Haas NB, Von Mehren M, Grosh WW. Randomized Multicenter Trial of the Effects of Melanoma-Associated Helper Peptides and Cyclophosphamide on the Immunogenicity of a Multipeptide Melanoma Vaccine. Journal of Clinical Oncology. 2011 Jul;29(21):2924-32.   PMCID: PMCID: PMC3138719[Available on 2012/7/20]
Sulmasy DP, Astrow AB, He MK, Seils DM, Meropol NJ, Micco E, Weinfurt KP. The Culture of Faith and Hope Patients' Justifications for Their High Estimations of Expected Therapeutic Benefit When Enrolling in Early Phase Oncology Trials. Cancer. 2010 Aug;116(15):3702-11.   PMCID: NIH funded - needs PMCID
Dritschilo A, Huang CH, Rudin CM, Marshall J, Collins B, Dul JL, Zhang CB, Kumar D, Gokhale PC, Ahmad A, Ahmad I, Sherman JW, Kasid UN. Phase I study of liposome-encapsulated c-raf antisense oligodeoxyribonucleotide infusion in combination with radiation therapy in patients with advanced malignancies. CLINICAL CANCER RESEARCH. 2006 Feb;12(4):1251-9.
Miller DS, Blessing JA, Waggoner S, Schilder J, Sorosky J, Bloss J, Schilder R. Phase II evaluation of 9-aminocamptothecin (9-AC, NSC #603071) in platinum-resistant ovarian and primary peritoneal carcinoma: A Gynecologic Oncology Group Study. Gynecologic Oncology. 2005 Jan;96(1):67-71.
Bono P, Krause A, von Mehren M, Heinrich MC, Blanke CD, Dimitrijevic S, Demetri GD, Joensuu H. Serum KIT and KIT ligand levels in patients with gastrointestinal stromal tumors treated with imatinib. Blood. 2004 Apr;103(8):2929-35.
Cheng JD, Hitt J, Koczwara B, Schulman KA, Burnett CB, Gaskin DJ, Rowland JH, Meropol NJ. Impact of quality of life on patient expectations regarding phase I clinical trials. Journal of Clinical Oncology. 2000 Jan;18(2):421-8.
Mandelblatt JS, Hadley J, Kerner JF, Schulman KA, Gold K, Dunmore-Griffith J, Edge S, Guadagnoli E, Lynch JJ, Meropol NJ, Weeks JC, Winn R. Patterns of breast carcinoma treatment in older women - Patient preference and clinical and physician influences. Cancer. 2000 Aug;89(3):561-73.
Lee WR, Berkey B, Marcial V, Fu KK, Cooper JS, Vikram B, Coia LR, Rotman M, Ortiz H. Anemia is associated with decreased survival and increased locoregional failure in patients with locally advanced head and neck carcinoma: A secondary analysis of RTOG 85-27. International Journal of Radiation Oncology Biology Physics. 1998 Dec;42(5):1069-75.
Clark JI, Alpaugh RK, vonMehren M, Schultz J, Gralow JR, Cheever MA, Ring DB, Weiner LM. Induction of multiple anti-c-erB-2 specificities accompanies a classical idiotypic cascade following 2B1 bispecific monoclonal antibody treatment. Cancer Immunology Immunotherapy. 1997 Jul;44(5):265-72.
Fein DA, Lee WR, Hanlon AL, Ridge JA, Langer CJ, Curran WJ, Coia LR. Pretreatment Hemoglobin Level Influences Local-Control and Survival of T1-T2 Squamous-Cell Carcinomas of the Glottic Larynx. Journal of Clinical Oncology. 1995 Aug;13(8):2077-83.
Odwyer PJ, Lacreta FP, Schilder R, Nash S, McAleer C, Miller LL, Hudes GR, Ozols RF. Phase-I Trial of Thiotepa in Combination with Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor. Journal of Clinical Oncology. 1992 Aug;10(8):1352-8.
Xiang J, Moyana T, Kalra J, Hamilton T, Qi YM. Construction and Characterization of a High-Affinity Chimeric Anticolorectal Carcinoma Antibody Ccm4. Molecular Biotherapy. 1992 Dec;4(4):174-83.
Yeung RS, Vollmer C, Taylor DD, Palazzo J, Weese JL. Intratumoral Ril2-Based Immunotherapy in B16 Melanoma. Journal of Surgical Research. 1992 Aug;53(2):203-10.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term cancer-patients

cancer-patients chemotherapy radiation-therapy trial breast-cancer anemia cells paclitaxel tumor necrosis factor therapy expression erythropoietin metastatic melanoma etanidazole antibody-dependent cellular i clinical-trials molecular-cloning expectations preferences adoptive immunotherapy cell-division c-kit improves vivo targeting c-erbb-2 misonidazole-sensitized radiotherapy laparotomy imaging conserving surgery a kinase critical reassessment mitotic arrest phase-i trial lysis irradiation cytotoxicity stem-cell factor informed-consent chimeric antibody carcinoembryonic antigen treatment choice informed consent human igg1 antibody risks antimitotic drugs lak cells c-raf-1 hypoxic cell sensitizer receptor b723 gemcitabine larynx genes vocal cord carcinoma carcinoma in-situ patterns of care hemoglobin level candidate regions colony-stimulating factor survival multivariate-analysis phase-ii sex reversal soluble kit advanced breast dose-fractionation age risk communication clinical trials-decision making-neoplasms-religion and medicine as topic oligonucleotide elderly patients 1992 rman d-v65-p255 squamous carcinoma resistant immunization 9-aminocamptothecin primary peritoneal carcinoma advanced gastric-carcinoma apoptosis breast carcinoma population care responses mediated-immunity facilitated adoptive immunotherapy oncology brothers carcinoma cell- myelosuppression colon cancer t-cells elderly misconception follow-up clinical-outcomes intralesional participation head and neck carcinoma inhibition invivo metabolism treatment ovarian cancer immune-response antitumor immune-response topotecan ovarian-cancer injection t-cell responses regression activated killer-cells gamma-interferon Oncology recombinant low-dose cyclophosphamide primary radiotherapy mesylate interleukin-2 pharynx carcinoma testis differentiation c-erbB-2 endothelial growth-factor stage hybrid hybridomas toxicity perceptions bispecific antibody lymphocytes uterine cervix gm-csf prognostic factors pharmacokinetics monoclonal-antibody myeloid-leukemia radiosensitizer complement-dependent cytotoxicity antigen CD16 of-life anti-tag72 antibody genome-wide association tyrosine kinase cisplatin adjustment
Last updated on Sunday, August 09, 2020